Exact Sciences Q1 EPS Estimate Boosted by Leerink Partnrs

Exact Sciences Co. (NASDAQ:EXAS) – Stock analysts at Leerink Partnrs increased their Q1 2025 earnings estimates for Exact Sciences in a research note issued to investors on Thursday, February 20th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings of ($0.06) per share for the quarter, up from their prior forecast of ($0.10). The consensus estimate for Exact Sciences’ current full-year earnings is ($0.58) per share. Leerink Partnrs also issued estimates for Exact Sciences’ Q2 2025 earnings at $0.03 EPS, Q1 2026 earnings at $0.10 EPS, Q3 2026 earnings at $0.26 EPS and Q4 2026 earnings at $0.34 EPS.

EXAS has been the topic of several other reports. BTIG Research upped their price target on shares of Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Stifel Nicolaus decreased their price objective on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Sanford C. Bernstein upped their price objective on shares of Exact Sciences from $75.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Evercore ISI decreased their price objective on shares of Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Finally, Barclays decreased their price objective on shares of Exact Sciences from $70.00 to $65.00 and set an “overweight” rating on the stock in a report on Thursday, February 20th. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $72.24.

Exact Sciences Stock Performance

NASDAQ EXAS opened at $50.18 on Monday. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. The firm’s fifty day moving average price is $54.52 and its two-hundred day moving average price is $59.95. Exact Sciences has a 1 year low of $40.62 and a 1 year high of $79.62. The firm has a market capitalization of $9.32 billion, a P/E ratio of -9.01 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The firm had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million.

Institutional Investors Weigh In On Exact Sciences

A number of large investors have recently bought and sold shares of the company. Integrated Advisors Network LLC grew its stake in Exact Sciences by 23.7% during the fourth quarter. Integrated Advisors Network LLC now owns 6,657 shares of the medical research company’s stock worth $374,000 after buying an additional 1,276 shares in the last quarter. Polar Asset Management Partners Inc. lifted its holdings in shares of Exact Sciences by 20.1% in the fourth quarter. Polar Asset Management Partners Inc. now owns 81,997 shares of the medical research company’s stock worth $4,607,000 after acquiring an additional 13,697 shares during the last quarter. Mackenzie Financial Corp lifted its holdings in shares of Exact Sciences by 107.7% in the fourth quarter. Mackenzie Financial Corp now owns 2,919,325 shares of the medical research company’s stock worth $164,037,000 after acquiring an additional 1,513,873 shares during the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its holdings in shares of Exact Sciences by 115.5% in the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 236,617 shares of the medical research company’s stock worth $13,296,000 after acquiring an additional 126,802 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Exact Sciences by 6.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,421,671 shares of the medical research company’s stock worth $79,884,000 after acquiring an additional 81,774 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.